The J&J CEO says individuals could also be taking pictures yearly for the subsequent a number of years

Johnson & Johnson Chairman and CEO Alex Gorsky celebrates the 75th anniversary of his company’s listing on the New York Stock Exchange on September 17, 2019.

Brendan McDermid | Reuters

For the next several years, people may need to be vaccinated against Covid-19 annually, just like seasonal flu shots, Johnson & Johnson CEO Alex Gorsky told CNBC on Tuesday.

“Unfortunately as [the virus] Spreads can also mutate, “he told CNBC’s Meg Tirrell during a Healthy Returns Spotlight event.” Every time it mutates, it’s almost like another click on the dial, so to speak, where we can see another variant, another mutation that can affect its ability to fight off antibodies or not just a therapeutic agent, but also react differently to a vaccine. “

Public health officials and infectious disease experts have indicated that Covid-19 is very likely to become an endemic disease, meaning it will be present in communities at all times, albeit likely at lower levels than it is now. Health officials must constantly look for new variants of the virus so scientists can make vaccines against them, medical experts say.

Gorsky’s comment came after J&J stated on Friday that it had applied for emergency clearance from the Food and Drug Administration for its coronavirus vaccine. Unlike Pfizer and Moderna’s vaccines, which require two doses three to four weeks apart, J&J only requires one dose, which makes logistics easier for healthcare providers.

US officials and Wall Street analysts are eagerly anticipating J & J’s vaccine approval, which could come as early as this month. President Joe Biden is trying to speed up the pace of vaccination in the U.S., and experts say his government will need a range of drugs and vaccines to beat the virus that killed more than 450,000 Americans last year at Johns Hopkins University .

The Department of Health and Human Services announced in August that it had signed a contract with Janssen, J & J’s pharmaceutical subsidiary, worth approximately $ 1 billion for 100 million doses of its vaccine. The deal gives the federal government the opportunity to order another 200 million cans, according to the announcement.

This is a developing story. Please try again.

Comments are closed.